MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacc.2022.08.747

Медицинская библиотека · Journal of the American College of Cardiology · 2022

Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction.

Stähli Barbara E, Klingenberg Roland, Heg Dik, Branca Mattia, Manka Robert, Kapos Ioannis, Müggler Oliver, Denegri Andrea, Kesterke Rahel, Berger Florence, Stehli Julia, Candreva Alessandro, von Eckardstein Arnold, Carballo David, Hamm Christian, Landmesser Ulf, Mach François, Moccetti Tiziano, Jung Christian, Kelm Malte, Münzel Thomas, Pedrazzini Giovanni, Räber Lorenz, Windecker Stephan, Templin Christian, Matter Christian M, Lüscher Thomas F, Ruschitzka Frank

Рандомизированное исследованиеМногоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Early inflammation following acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) affects myocardial infarct (MI) size and left ventricular remodeling. The mammalian target of rapamycin (mTOR) is involved in the enhanced inflammatory response and its inhibition has exerted beneficial effects on MI size in preclinical models of acute MI.

OBJECTIVES

The CLEVER-ACS (Controlled Level Everolimus in Acute Coronary Syndromes) trial evaluated the effects of targeting inflammation by mTOR inhibition in patients with STEMI undergoing PCI.

METHODS

CLEVER-ACS was a randomized, multicenter, international, double-blind, placebo-controlled trial. A total of 150 patients with STEMI undergoing PCI were randomly assigned to oral everolimus (days 1-3: 7.5 mg daily; days 4-5: 5.0 mg daily) or placebo for 5 days. The primary endpoint was the change in MI size. The secondary endpoint was the change in microvascular obstruction (MVO) from baseline (12 hours to 5 days after PCI) to 30 days as assessed by cardiac magnetic resonance imaging.

RESULTS

The changes in MI size from baseline to 30 days, the primary endpoint, were -14.2 g (95% CI: -17.4 to -11.1 g) and -12.3 g (95% CI: -16.0 to -8.7 g) in the everolimus and placebo groups (P = 0.99). Corresponding changes in MVO were -4.8 g (95% CI: -6.7 to -2.9 g) and -6.3 g (95% CI: -8.7 to -4.0 g) in the everolimus and placebo groups (P = 0.14). Adverse events did not differ between the study groups.

CONCLUSIONS

Among STEMI patients undergoing PCI, early mTOR inhibition with everolimus did not reduce MI size or MVO at 30 days. (CLEVER-ACS [Controlled Level Everolimus in Acute Coronary Syndromes; NCT01529554).

Для цитирования: Stähli Barbara E, Klingenberg Roland, Heg Dik, Branca Mattia, Manka Robert, Kapos Ioannis, Müggler Oliver, Denegri Andrea, Kesterke Rahel, Berger Florence, Stehli Julia, Candreva Alessandro, von Eckardstein Arnold, Carballo David, Hamm Christian, Landmesser Ulf, Mach François, Moccetti Tiziano, Jung Christian, Kelm Malte, Münzel Thomas, Pedrazzini Giovanni, Räber Lorenz, Windecker Stephan, Templin Christian, Matter Christian M, Lüscher Thomas F, Ruschitzka Frank. Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction.. Journal of the American College of Cardiology. 2022. DOI: 10.1016/j.jacc.2022.08.747.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.